Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Wilfried Eberhardt, MD
CONTACT
Mathias Hoiczyk
CONTACT
Lead
Universität Duisburg-Essen
With
There is a current need to develop a split-dose cisplatinum regimen in combination with pemetrexed with high efficacy, excellent treatment compliance, administration convenience and the possibility to open up easier outpatient administration of the chemotherapy protocol. Dosing of cisplatinum at 40 mg/m2 d 1 and day 8 seems to be very effective and useful for this strategy. The current trial will address this issue within a prospective randomized phase-II trial. Treatment will be given on day 1 and 8 in the split-dose arm. A comparator arm of the current three-weekly higher cisplatinum schedule will be added to this study. For evaluation of this strategy observation of the toxicity/efficacy ratio within this trial will be of major importance. Efficacy will be analyzed by objective response rate, symptom control and life-quality. Toxicity will be looked at with treatment toxicity, treatment compliance and adherence to protocol.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
